SeraCare Life Sciences, Inc. company was founded in 1984 and is headquartered in Milford, Massachusetts. SeraCare Life Sciences, Inc., a life sciences company, provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company’s portfolio includes diagnostic controls, plasma-derived reagents, and molecular biomarkers, as well as biobanking and contract research services. It operates in two segments, Diagnostic & Biopharmaceutical Products and BioServices. The Diagnostic & Biopharmaceutical Products segment provides controls and panels used for the evaluation and quality control of infectious disease tests in hospitals and clinical labs, blood banks, and in vitro diagnostic (IVD) manufacturing; and reagents and bioprocessing products, including biological materials for use in the research, development, and manufacture of human and animal diagnostics, therapeutics, and vaccines. This segment sells various controls and panels to hospital laboratories, independent clinical laboratories, public health laboratories, blood banks, IVD manufacturers, and government regulatory and research agencies; and reagents and bioprocessing products to diagnostic, pharmaceutical, and biotechnology product developers and manufacturers, as well as to research laboratories affiliated with government, academia, and private foundations.

Orbus Pharma offers pharmaceutical research, manufacturing, packaging, and warehousing services on a contract basis for other drug companies. Orbus Pharma specializes in oral suspension and generic pharmaceutical products. The company serves the North American, European, and other international markets. It develops formulations of existing drugs using proprietary delivery systems and then provides out-licensing and contract manufacturing services for the products. Orbus has agreed to allow China-based pharmaceutical firm Nanjing Sanhome Pharmaceutical Co. to acquire a majority of its shares.

ROHTO Pharmaceutical Co., Ltd. company was founded by Yasutami Yamada in 1899 as Shintendo Yamada Anmin Pharmacy. Later, it changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical is headquartered in Osaka, Japan. Rohto Pharmaceutical Co., Ltd. engages in the manufacture and marketing of pharmaceutical and other healthcare products in Japan and internationally. It primarily offers eye care, skin care, and oral medicine and supplement products. The company's eye care products include eye drops, eye wash preparations, and contact lens care products. Its eye care products spreads moisture over the surface of the eyes, suppresses allergy and works on ocular itching, as well as are used for the treatment of sties and conjunctivitis, inflammation or itching caused by bacteria on lenses, and eye disease causing pollens and house dust.Rohto company's skin care products include dermal medicines, which are used for the treatment of dry skin and females' anorectal discomforts; lip care products that are used for the prevention of dry, sore, and roughness of lips; and hand, body, sun, and acne care products. Rohto Pharmaceutical's oral medicine and supplement products include `Pansion' brand products, which are primarily used for the treatment of gastric discomfort, mucosal repair agents and stomachics for improving damaged gastric mucosa, stomach pain, and heartburn and other hyperacidity-related symptoms. It also offers a range of test products, including blood sugar testing kits, ovulation self-test kits, and pregnancy self-test kits; and denture cleansers.

Access Pharmaceuticals, Inc. was founded in 1988 and is based in Dallas, Texas. Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

VaxGen, Inc. company was founded in 1995 and is based in South San Francisco, California. VaxGen, Inc., (VaxGen) is a biopharmaceutical company. VaxGen is focused on the development, manufacture and commercialization of biologic products for the treatment of human disease. The Company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. The Company has ended all product development activities and sold or otherwise terminated its drug development programs. On March 28, 2008, the Company entered into a Termination of Merger Agreement, Acknowledgment and Amendment to Loan Agreement and Secured Promissory Note, or Termination Agreement and Amendment, terminating immediately the Merger Agreement and amending the terms of VaxGen’s bridge loan to Raven.

Shanghai Pharmaceutical Group, or SPGC, knows that Big Pharma is big business. One of China's largest pharmaceutical companies, SPGC makes over-the-counter (OTC) medicines, prescription drugs, active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicine. The vertically-integrated company distributes its wares and owns more than 1,000 retail locations. SPGC sells drugs in 30 countries from five foreign offices. Its R&D facility, Central Research Institute, operates 10 centers across China. In 1996 many small producers, including Sine, Dragon & Tiger, and Pioneer, merged to form SPGC.

Medicure Inc., (Medicure) is a biopharmaceutical company engaged in the research and development and commercialization of human therapeutic. The Company's primary focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) in the United States and its territories through its United States subsidiary, Medicure Pharma Inc. The Company's primary research and development program of focus is the clinical development of TARDOXAL (product previously referred to as AVASTREM) for neurological disorders, although the Company continues to investigate and advance certain other product opportunities.

Emergent BioSolutions Inc. company was founded in 1998 and is based in Rockville, Maryland. mergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The company's earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency.

Ore Pharmaceuticals Inc. company was founded in 1994 and is headquartered in Cambridge, Massachusetts. Ore Pharmaceutical Holdings Inc., through its wholly owned subsidiary, Ore Pharmaceuticals Inc., operates as a drug development company in the United States. Its drug candidates include GL1001, the lead drug candidate that completed a multiple ascending dose Phase I clinical trial, for the treatment of inflammatory bowel disease; tiapamil for treatment of diseases of central nervous system, primarily focused on cognition and memory; and romazarit, a clinical-stage drug candidate for the treatment of metabolic indications, such as obesity.

CombinatoRx, Incorporated company was founded in 2000 and is based in Cambridge, Massachusetts. CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. In December 2009, CombinatoRx and Neuromed Pharmaceuticals Inc. announced that they have merged.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.